Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RU78299
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
RU78299 is a small molecule investigational compound classified as a phenyl phosphate derivative. Its chemical formula is C9H9O6P and it is also known as (2,6-diformyl-4-methylphenoxy)phosphonic acid. RU78299 functions as an inhibitor of the proto-oncogene tyrosine-protein kinase Src (commonly referred to as Src kinase), which plays a key role in cellular signaling pathways involved in cancer and other proliferative diseases. The compound has been studied primarily for its potential anti-cancer properties due to its ability to inhibit Src kinase activity[1][3][4].
- Other names
- (2,6-diformyl-4-methylphenoxy)phosphonic acid2,6-DIFORMYL-4-METHYLPHENYL DIHYDROGEN PHOSPHATE
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on RU78299.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RU78299.